drugset
drugset / Trial / NCT04772612

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

NCT04772612 ↗

Phase 1 Completed 30 enrolled Mirati Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib

Timeline

Start
2021-03-12
Primary completion
2022-07-13
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitravatinib Small molecule 100 mg —

Indications

No indication recorded.